Evolving treatment strategies for the management of type 2 diabetes

American Journal of the Medical Sciences

Volumn 343, Issue 1, 2012, Pages 21-26

  Cefalu, William T ^a,b  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Diabetes; Incretins; Treatment

Indexed keywords

ALOGLIPTIN; ANTIDIABETIC AGENT; CANAGLIFLOXIN; DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIPIZIDE; GLITAZONE DERIVATIVE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INCRETIN; INSULIN; INSULIN GLARGINE; LIRAGLUTIDE; METFORMIN; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; REPAGLINIDE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; UNCLASSIFIED DRUG; VILDAGLIPTIN;

ADD ON THERAPY; CONFERENCE PAPER; CONTINUOUS INFUSION; DRUG SAFETY; GLUCONEOGENESIS; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; SIDE EFFECT; TREATMENT PLANNING; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 84855257784     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e31823ea4af     Document Type: Conference Paper

References (48)

1. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-53.
2. Holman RR, Paul SK, Bethel MA, et al. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89.
3. American Diabetes Association. Standards of medical care in diabetes - 2011. Diabetes Care 2011;34:S11-61.
4. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002;287:2563-9.
5. The Action to Control Cardiovascular Risk in Diabetes Study Group Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59.
6. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72.
7. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-39.
8. Riddle MC, Ambrosius WT, Brillon DJ, et al.; Action to Control Cardiovascular Risk in Diabetes Investigators. Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care 2010;33:983-90.
9. Cefalu WT. Pharmacotherapy for the treatment of patients with type 2 diabetes mellitus: rationale and specific agents. Clin Pharmacol Ther 2007;81:636-49. (Pubitemid 46625117)
10. Cefalu WT. The physiologic role of incretin hormones: clinical applications [review]. J Am Osteopath Assoc 2010;110(3 Suppl 2):S8-14.
11. Cefalu WT, Richards RJ, Melendez-Ramirez LY, et al. Redefining treatment success in type 2 diabetes mellitus: comprehensive targeting of core defects. Cleve Clin J Med 2009;76(Suppl 5):S39-47.
12. Del Prato S, Felton AM, Munro N, et al. Global Partnership for Effective Diabetes Management. Improving glucose management: ten steps to get more patients with type 2 diabetes to glycaemic goal. Recommendations from the Global Partnership for Effective Diabetes Management. Int J Clin Pract 2005;59:1345-55.
13. Campbell IW. Need for intensive, early glycaemic control in patients with type 2 diabetes. Br J Cardiol 2000;7:625-31.
14. Del Prato S, LaSalle J, Matthaei S, et al. Global Partnership for Effective Diabetes Management. Tailoring treatment to the individual in type 2 diabetes practical guidance from the Global Partnership for Effective Diabetes Management. Int J Clin Pract 2010;64:295-304.
15. Müller WA, Faloona GR, Aguilar-Parada E, et al. Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. N Engl J Med 1970;283:109-15.
16. Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773-95.
17. DeFronzo RA, Ferrannini E, Simonson DC, et al. Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism 1989;38:387-95. (Pubitemid 19105727)
18. Baron AD, Schaeffer L, Shragg P, et al. Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics. Diabetes 1987;36:274-83. (Pubitemid 18028415)
19. Kooy A, de Jager J, Lehert P, et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med 2009;169:616-25.
20. Cefalu WT. Diabetes: HOME reveals new data on a cornerstone of treatment. Nat Rev Endocrinol 2009;5:478-9.
21. Riddle MC. Glycemic management of type 2 diabetes: an emerging strategy with oral agents, insulins, and combinations. Endocrinol Metab Clin North Am 2005;34:77-98. (Pubitemid 40332504)
22. Riddle MC. Making the transition from oral to insulin therapy. Am J Med 2005;118(Suppl 5A):14S-20S. (Pubitemid 40585811)
23. Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003;26:2929-40. (Pubitemid 37205571)
24. Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev 1999;20:876-913. (Pubitemid 30647076)
25. Deacon CF, Nauck MA, Toft-Nielsen M, et al. Both subcutaneously and intravenously administered glucagon-like peptide 1 are rapidly degraded from the NH2-terminus in Type II diabetic patients and in healthy subjects. Diabetes 1995;44:1126-31.
26. Herman GA, Bergman A, Stevens C, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 2006;91:4612-9. (Pubitemid 44833446)
27. Nauck MA, Meininger G, Sheng D, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007;9:194-205.
28. Olansky L, Reasner C, Seck TL, et al. Treatment strategy implementing combination therapy with sitagliptin and metformin results in superior glycaemic control versus metformin monotherapy due to a low rate of addition of antihyperglycaemic agents. Diabetes Obes Metab 2011;13:841-9.
29. Bailey CJ, Green BD, Flatt PR, et al. Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone [review]. Expert Opin Investig Drugs 2010;19:1017-25.
30. Rosenstock J, Aguilar-Salinas C, Klein E, et al.; CV181-011 Study Investigators. Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes. Curr Med Res Opin 2009;25:2401-11.
31. DeFronzo RA, Hissa MN, Garber AJ, et al.; Saxagliptin 014 Study Group. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009;32:1649-55.
32. Chacra AR, Tan GH, Ravichandran S, et al.; CV181040 Investigators. Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks. Diab Vasc Dis Res 2011;8:150-9.
33. Nauck MA, Ellis GC, Fleck PR, et al.; Alogliptin Study 008 Group. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. Int J Clin Pract 2009;63:46.
34. Pratley RE, Reusch JE, Fleck PR, et al.; Alogliptin Study 009 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin 2009;25:2361-71.
35. Scheen AJ. Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation). Expert Opin Drug Metab Toxicol. 2011;7(12):1561-76.
36. Garber AJ. Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability. Diabetes Care 2011;34(Suppl 2):S279-84.
37. Levin PA, Mersey JH, Zhou S, et al. Clinical outcomes using long-term combination therapy with insulin glargine and exenatide in patients with type 2 diabetes. Endocr Pract 2011;8:1-28.
38. Bunck MC, Cornér A, Eliasson B, et al. Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes. Diabetes Care 2011;34:2041-7.
39. Russell-Jones D. Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue. Mol Cell Endocrinol 2009;297:137-40.
40. Marre M, Shaw J, Brändle M, et al. Liraglutide,1a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009;26:268-78.
41. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009;32:84-90.
42. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009;373:473-81.
43. Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009;32:1224-30.
44. Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009;52:2046-55.
45. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374:39-47.
46. Neumiller JJ, White JR Jr, Campbell RK, et al. Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus. Drugs 2010;70:377-85.
47. Chao ED. A paradigm shift in diabetes therapy - dapagliflozin and other SGLT2 inhibitors. Discov Med 2011;11:255-63.
48. Sha S, Devineni D, Ghosh A, et al. A novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab 2011;13:669-72.